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Retrospective analysis reveals 
significant association of 
hypoglycemia with tramadol and 
methadone in contrast to other 
opioids
tigran Makunts1, Andrew U1, Rabia S. Atayee1,2 & Ruben Abagyan1
Tramadol is one of the most commonly used analgesics worldwide, classified as having a low abuse 
potential by U.S. Drug Enforcement Agency, and often recommended in pain management guidelines. 
Its pain-relieving mechanism of action is attributed to mild μ-opioid receptor agonism, serotonin and 
norepinephrine mediated nociception modulation, and n-methyl-D-aspartate receptor, nMDAR, 
antagonism. However, recent case reports and case-control studies have shown an association 
between tramadol use and hypoglycemia. the growing concern over increasing tramadol use and 
unexpected side effects warranted a further comparative and quantitative analysis of tramadol adverse 
reactions. In this study we analyzed over twelve million reports from United States Food and Drug 
Administration Adverse Event Reporting System and provided evidence of increased propensity for 
hypoglycemia in patients taking tramadol when compared to patients taking other opioids, serotonin-
norepinephrine reuptake inhibitors, and drugs affecting NMDAR activity. Additionally, we identified 
that only methadone from the opioid cohort behaves similarly to tramadol and has an association with 
hypoglycemia.
Tramadol, a synthetic centrally acting weak opioid analgesic approved in 1995, has gradually gained increased 
worldwide use for acute and chronic pain management due to its low risk of respiratory depression, compared 
to other opioids1,2. Tramadol currently ranks in the top five prescribed opioids and in the top sixty prescribed 
medications in the United States3. According to the 2017 CDC Census Report, prescriptions for tramadol and 
other synthetic opioids have increased by 88% from 2008 to 20134. Tramadol adverse reaction-related hospital 
visits have increased two fold since 2005, with female patients accounting for the majority of cases5,6. In response 
to increased tramadol use and its potential for abuse, the Drug Enforcement Agency (DEA) recognized a higher 
potential of abuse and recategorized tramadol from Schedule V to Schedule IV of the Controlled Substance Act 
in 2014.
Tramadol’s analgesic effect originates from two distinct mechanisms. It increases the pain threshold by acting 
on serotonergic and noradrenergic nociception via serotonin and norepinephrine reuptake inhibition (SNRI), 
and its metabolite, O-desmethyltramadol, acts as a μ-opioid receptor agonist (MOR)7–9. Additionally tramadol 
has an inhibitory effect on N-methyl-D-aspartate receptors (NMDARs)10, which are involved in somatic and 
visceral nociception11. Recognized adverse drug reactions (ADRs) of tramadol, common to all opioids, include 
dizziness/vertigo, nausea, constipation, headache, somnolence, vomiting, pruritus, and others12. Rare but serious 
side effects include serotonin syndrome and increased seizure risk12. In addition, recent studies have reported 
new and unexpected side effect associated with tramadol use.
There have been several case reports describing hypoglycemia induced by tramadol and resolved upon 
its discontinuation13–16.These incidences occurred in both patients with and without diabetes. Hypoglycemia 
ADR is of great concern since it can lead to many serious complications including neurocognitive dysfunction, 
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retinal cell damage and vision loss, risk of falls, and other complications affecting health and quality of life17. In 
a nested case-control study, Fournier et al. identified an association of tramadol use with hypoglycemia when 
compared to patients taking codeine18. In a later case-control study this association was confirmed by Golightly 
et al. where patients taking tramadol were compared to patients on oxycodone19. Studies based on animal mod-
els have demonstrated that tramadol directly induced glucose utilization by hepatocytes and skeletal muscles 
of streptozotocin-induced diabetic rats via μ-opioid receptor activation20,21. Other animal studies have demon-
strated the role of serotonin in glucose metabolism via insulin modulation22,23. Based on previous evidence from 
animal studies, tramadol induced hypoglycemia has been attributed to MOR agonism or serotonin modulation. 
Another possible etiology of hypoglycemia could be related to NMDAR antagonism10,24–30.
In this study we posed two questions: (1) is tramadol use significantly associated with an elevation of hypogly-
cemia reports in non-diabetic patients, (2) is hypoglycemia associated with any other opioids, SNRIs, or NMDAR 
modulators. SNRI and NMDAR modulators were selected as comparison patient treatment categories because 
they represent two non-opioid activities of tramadol.
Here we analyzed over twelve million ADR reports from United States FDA Adverse Event Reporting System 
(FAERS) and found a significant association of tramadol use with hypoglycemia. Among eleven opioids, four 
Figure 1. Inclusion, exclusion and analysis cohort selection for adverse event rate comparison between 
tramadol, non-tramadol opioid, SNRI and NMDAR antagonist cohorts.
Tramadol 
(n = 6,355)
Frequency 
(%)
Opioids 
(n = 77,307)
Frequency 
(%)
SNRIs 
(n = 45,201)
Frequency 
(%)
NMDAR 
antagonists 
(n = 16,541)
Frequency 
(%)
Female 3,035 47.8 36,439 47.1 30,663 67.8 8,081 48.9
Male 2,190 34.5 29,960 38.8 10,526 23.3 6,455 39.0
Unreported 1,130 17.8 10,908 14.1 4,012 8.9 2,005 12.1
Mean age, years (SD) 46.1 (22.7) 49.2 (21.3) 49.1 (18.4) 30.0 (24.7)
Median age, years 51 52.7 49.8 47.3
Unreported (%) 46.7 58.1 52.3 34.9
Table 1. Patient demographics in tramadol, non-tramadol opioid, SNRI and NMDAR antagonist cohorts.
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SNRIs and five NMDAR-antagonists that were analyzed, only methadone was associated with hypoglycemia sim-
ilarly to tramadol.
Methods
fDA adverse event reporting system (fAeRS/AeRS). Over twelve million adverse event reports were 
acquired from the FDA Adverse Event Reporting System (FAERS) and its older version Adverse Event Reporting 
System (AERS) data sets. At the time of the analysis the FAERS data set contained adverse effect reports from 
September 2012 to March 2019 and the AERS set contained data from January 2004 to August 2012. FAERS/
AERS is a repository of post-marketing surveillance records on therapeutic agents reported to the FDA through 
MedWatch. The database consists of voluntary reports by pharmacists, physicians, patients, legal representatives, 
and other healthcare providers. Adverse events submitted directly to the manufacturer are legally required to be 
forwarded to FAERS/AERS.
Both FAERS and AERS data sets are available online at: http://www.fda.gov/Drugs/GuidanceCompliance 
RegulatoryInformation/Surveillance/AdverseDrugEffects/ucm082193.htm.
combining and normalizing the data. FAERS/AERS online reports were posted quarterly and were 
downloaded in sets of seven tables for each quarter in dollar separated text (.TXT) format. The data from the 
tables were extracted and joined into a consistent format for analysis. Demographic parameters were converted 
into single standard units to facilitate filtering and selections. The column names were unified and missing col-
umns in older data sets were added with no values. The final version of the data set contained reports from the 
first quarter of 2004 to the first quarter of 2019. All international and domestic drug names of interest were trans-
lated to their corresponding United States Adopted Names Council approved generic names31–33.
cohort selection. A total of 12,004,552 FAERS/AERS reports were collected. Reports containing tramadol, 
codeine, hydrocodone, oxycodone, oxymorphone, hydromorphone, morphine, fentanyl, methadone, dextropro-
poxyphene, and tapentadol used as monotherapy were separated into their respective cohorts. Similarly, selec-
tion was performed for the following SNRIs: duloxetine, venlafaxine, desvenlafaxine, and milnacipran used as 
monotherapy, and drugs with NMDAR activity: minocycline, atomoxetine, ketamine, dextromethorphan, and 
memantine.
Monotherapy was defined in these cases as reports where each patient was using only the medication of 
interest. A total of 145,404 monotherapy reports were analyzed: opioids (n = 83,662), SNRIs (n = 45,201), and 
NMDAR antagonists (n = 16,541). Reports where the diabetes indication was listed or where the medications 
were used to treat diabetic neuropathy were excluded (Fig. 1). Reports submitted by lawyers or consumers were 
excluded from the analysis due to higher potential for bias and misclassification. FAERS data sets included follow 
up reports with the same case identifier. These constituted 0.04% of the total reports and were also excluded from 
the analysis (Fig. 1). Demographic analysis was performed for tramadol, other opioid, SNRI, and NMDAR antag-
onist cohorts to illustrate the availability and the comparability of the chosen cohorts (Table 1).
Figure 2. (a) Frequencies of hypoglycemia events for patients on tramadol (n = 6,355), opioids (n = 83,662), 
SNRIs (n = 45,201), and NMDAR antagonists (n = 16,541). (b) Odds ratios were calculated comparing 
frequencies of hypoglycemia reports from the tramadol cohort and each of the opioid, SNRI and NMDAR 
antagonist cohorts. Ranges represent 95% confidence intervals (95% CI) (see Methods). X-axis is presented 
in log scale. Abbreviations: TRA-tramadol, SNRI-serotonin norepinephrine reuptake inhibitor, NMDAR-N-
methyl-D-aspartate receptor.
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Opioids included in this study were codeine (n = 1,031), dextropropoxyphene (n = 256), fentanyl (n = 28,538), 
hydrocodone (n = 5,641), hydromorphone (n = 2,103), methadone (n = 4,234), morphine (n = 11,431), oxyco-
done (n = 19,824), oxymorphone (n = 1,984), tapentadol (n = 2,265), and tramadol (n = 6,355).
SNRIs included in this study were desvenlafaxine (n = 8,688), duloxetine (n = 22,892), milnacipran (n = 969), 
venlafaxine (n = 12,652).
Figure 3. Frequencies of hypoglycemia events for patients on codeine (n = 1,030), dextropropoxyphene 
(n = 256), fentanyl (n = 28,538), hydrocodone (n = 5,641), hydromorphone (n = 2,103), methadone 
(n = 4,234), morphine (n = 11,431), oxycodone (n = 19,824), oxymorphone (n = 1,984), tapentadol (n = 2,265), 
tramadol (n = 6,355), desvenlafaxine (n = 8,688), duloxetine (n = 22,892), milnacipran (n = 969), venlafaxine 
(n = 12,652), atomoxetine (n = 8,417), dextromethorphan (n = 2,939), ketamine (n = 620), memantine 
(n = 2,120), and minocycline (n = 2,445).
Drug ROR 95% CI
Opioids
TRA vs Codeine 11.80 [1.64, 85.03]
TRA vs Dextropropoxyphene *
TRA vs Fentanyl 32.69 [16.86, 63.38]
TRA vs Hydrocodone 16.15 [5.89, 44.23]
TRA vs Hydromorphone 6.01 [2.19, 16.48]
TRA vs Methadone 1.29 [0.87, 1.93]
TRA vs Morphine 26.19 [10.57, 64.86]
TRA vs Oxycodone 13.35 [7.86, 22.67]
TRA vs Oxymorphone *
TRA vs Tapentadol *
SNRIs
TRA vs Desvenlafaxine 19.90 [8.03, 49.29]
TRA vs Duloxetine 14.56 [8.68, 24.43]
TRA vs Milnacipran *
TRA vs Venlafaxine 5.16 [3.34, 8.00]
NMDAR antagonists
TRA vs Atomoxetine 13.77 [6.33, 29.93]
TRA vs Dextromethorphan *
TRA vs Ketamine *
TRA vs Memantine 6.06 [2.22, 16.61]
TRA vs Minocycline 13.99 [3.43, 57.10]
Table 2. Reporting odds ratios were calculated comparing frequencies of hypoglycemia reports from the 
tramadol cohort and each of the individual drugs in the opioid, SNRI and NMDAR antagonist cohorts. Ranges 
represent 95% confidence intervals (95% CI) (see Methods). *Represents cohorts with no hypoglycemia reports.
5Scientific RepoRtS |         (2019) 9:12490  | https://doi.org/10.1038/s41598-019-48955-y
www.nature.com/scientificreportswww.nature.com/scientificreports/
Drugs with NMDAR antagonist activity were atomoxetine (n = 8,417), dextromethorphan (n = 2,939), keta-
mine (n = 620), memantine (n = 2,120), and minocycline (n = 2,445).
Odd ratios were calculated using relative frequencies of hypoglycemia reports for tramadol when compared 
to other opioids, SNRIs and NMDAR antagonists. The term hypoglycemia was used because of its strict clinical 
definition (plasma glucose concentration below 70 mg/dL) and because it is the preferred MedDRA term used 
in FAERS reports. The common symptoms of hypoglycemia were not used for the search due to their variability, 
lower specificity, and wide presence in other disease states. The term ‘decreased blood glucose’ was not included 
in the search since it was much less frequent, and not equivalent to hypoglycemia since it may correspond to levels 
over 70 mg/dL. The query was performed with only one term ‘hypoglycemia’ in the ADR field for the selected 
monotherapy cohorts.
Statistical analysis. Descriptive statistics. Frequencies for hypoglycemia ADRs were calculated by the 
equation:
= ∗Frequency (Number of Records with ADR)/(Number of Patient Records) 100 (1)
Comparative statistics. ADR report rates were compared via the Reporting Odds Ratio (ROR) disproportional-
ity analysis using the following equations:
=ROR (a/b)/(c/d) (2)
where
a: Number of cases in exposed group with an adverse event.
b: Number of cases in exposed group with no adverse event.
c: Number of cases in control group with the adverse event.
d: Number of cases in control group with no adverse event.
Figure 4. Reporting odds ratios were calculated comparing frequencies of hypoglycemia reports from 
the tramadol cohort and each of the opioid, SNRI and NMDAR antagonist cohorts. Ranges represent 95% 
confidence intervals (95% CI) (see Methods). X-axis is presented in log scale. Abbreviations: TRA-tramadol, 
SNRI-serotonin norepinephrine reuptake inhibitor, NMDAR-N-methyl-D-aspartate receptor.
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=LnROR Ln(ROR) (3)
Standard Error of Log Reporting Odds Ratio;
= √ + + +SE (1/a 1/b 1/c 1/d) (4)LnROR
95% Confidence Interval;
= − . × + . ×95%CI [exp(LnROR 1 96 SE ), exp(LnROR 1 96 SE )] (5)LnROR LnROR
Results
tramadol and hypoglycemia. Frequencies of hypoglycemia reports were initially calculated for opioids, 
SNRIs and NMDAR antagonists as a class, for comparison with hypoglycemia reports in the tramadol cohort 
(Fig. 2a). There was a significant elevation in hypoglycemia reports in the tramadol cohort when compared to opi-
oids-class: ROR 11.36, 95% confidence interval (CI) (8.23, 15.66), SNRIs-class: 10.14 (7.08, 14.54), and NMDAR 
antagonists-class 14.57 (8.07, 26.31) (Fig. 2b). This comparison emphasizes the special role of tramadol in causing 
hypoglycemia ADR unrelated to the pharmacology common to each of the studied drug classes.
This finding led us to study the individual drugs in each class which are known to have multitarget drug spe-
cific pharmacology and ADR profiles.
Hypoglycemia in eleven individual opioid cohorts. Frequencies of FAERS/AERS hypoglycemia 
reports were calculated for each of the opioids (Fig. 3). Patients who used tramadol as monotherapy had a signif-
icant elevation in the frequency of hypoglycemia when compared to nine opioids with mean ROR values ranging 
from 6 to 33 (Table 2 and Fig. 4). Interestingly, no significant difference was found in hypoglycemia frequencies 
between tramadol and methadone cohorts with 95% CI covering the value of 1: ROR. Not a single report with the 
hypoglycemia ADR was found in the tapentadol, oxymorphone, and dextropropoxyphene cohorts.
Hypoglycemia in four individual SNRI cohorts. Each of the SNRIs were analyzed for hypoglycemia 
report frequencies.
Patients who used tramadol as monotherapy had a significant elevation in the frequency of hypoglycemia 
when compared to patients taking each of the four SRNIs with mean ROR values ranging from 5 to 20. The mil-
nacipran cohort did not have any reports of hypoglycemia. (Table 2 and Fig. 4).
Hypoglycemia in five NMDAR antagonist reports. Reports where tramadol was used had a signifi-
cant elevation in the frequency of hypoglycemia when compared to patients taking each of the five drugs with 
NMDAR antagonist activity with mean ROR values in the range of 6–14. The ketamine and dextromethorphan 
cohorts did not have any reports of hypoglycemia ADR (Table 2 and Fig. 4).
ADRs co-occurring with hypoglycemia %
Hypoglycemia 100.00
Convulsion 22.89
Toxicity to various agents 16.87
Loss of consciousness 12.05
Overdose 10.84
Depressed level of consciousness 10.84
Vomiting 7.23
Malaise 7.23
Intentional overdose 7.23
Suicide attempt 6.02
Suicidal ideation 6.02
Seizure 6.02
Hypoglycemic coma 6.02
Hypoxia 4.82
Road traffic accident 3.61
Hypotension 3.61
Hyperhydrosis 3.61
Neonatal drug withdrawal syndrome 3.61
Dizziness 3.61
Altered state of consciousness 3.61
Accidental overdose 3.61
Table 3. ADRs co-occurring with hypoglycemia in the tramadol monotherapy cohort. ADR occurrences over 
3% are reported.
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Figure 5. Reporting Odds ratios were calculated comparing frequencies of hypoglycemia reports from the 
methadone cohort and each of the opioid and NMDAR antagonist cohorts. Ranges represent 95% confidence 
intervals (95% CI) (see Methods). X-axis is presented in log scale. Abbreviations: MTD-methadone, NMDAR-
N-methyl-D-aspartate receptor.
Drug ROR 95% CI
Opioids
MTD vs Codeine 9.08 [1.24, 66.25]
MTD vs Dextropropoxyphene *
MTD vs Fentanyl 25.15 [12.50, 50.61]
MTD vs Hydrocodone 12.42 [4.43, 34.88]
MTD vs Hydromorphone 4.63 [1.65, 13.00]
MTD vs Morphine 20.15 [7.91, 51.29]
MTD vs Oxycodone 10.27 [5.78, 18.26]
MTD vs Oxymorphone *
MTD vs Tapentadol *
MTD vs Tramadol 0.77 [0.52, 1.15]
NMDAR antagonists
MTD vs Atomoxetine 10.59 [4.72, 23.78]
MTD vs Dextromethorphan *
MTD vs Ketamine *
MTD vs Memantine 4.66 [1.66, 13.10]
MTD vs Minocycline 10.77 [2.59, 44.72]
Table 4. Reporting Odds ratios were calculated comparing frequencies of hypoglycemia reports from the 
methadone cohort and each of the opioid and NMDAR antagonist cohorts. Ranges represent 95% confidence 
intervals (95% CI) (see Methods). *Represents cohorts with no hypoglycemia reports.
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co-occurring ADRs. The top ADRs co-occurring with hypoglycemia were relatively rare but consistent 
hypoglycemia for tramadol. These included ‘loss of consciousness’ and ‘hypoglycemic coma’ (Table 3).
comparing methadone with ten other opioids and nMDAR antagonists. Similar analysis was per-
formed to evaluate hypoglycemia report frequency in the methadone monotherapy cohort (Fig. 5). Methadone’s 
analgesic effect is attributed to MOR agonism34,35 and NMDAR antagonism27,36. Patients who used meth-
adone as monotherapy had a significant elevation in the frequency of hypoglycemia when compared to nine 
(non-tramadol) opioids (mean ROR in the range of 4 to 26), and five other drugs with NMDAR antagonist 
activity (mean ROR in the range of 4 to 11) (Table 4 and Fig. 5). As expected there was no significant difference 
between hypoglycemia reports in the methadone cohort when compared to the tramadol cohort. Similarity in the 
ROR profile between both tramadol and methadone vs other drugs in the same class further supports a mecha-
nism of hypoglycemia unrelated to their common class-wide mechanisms of action.
co-occurring ADRs. Interestingly, the co-occurring (non-hypoglycemia-related) ADRs for methadone 
(Table 5), were mostly of cardiovascular nature. Hypoglycemia related ADRs were ‘hyper-insulinemic hypoglyce-
mia’ and ‘increased blood insulin’. The overlapping ADRs were consistent with opioid toxicity.
Discussion
To our knowledge, this study was the first analysis of the FDA Adverse Event Reporting System (FAERS) and its 
older version Adverse Event Reporting System (AERS) to generate a risk profile of tramadol’s association with 
hypoglycemia when compared to other opioids, SNRIs, and NMDAR modulators. In this study we quantified the 
association between tramadol exposure and hypoglycemia. By utilizing a total of 145,404 monotherapy reports 
for twenty therapeutics, we compared the reporting odds ratios of hypoglycemia reports and identified two drugs, 
tramadol and methadone, with higher risk. We were able to confirm the previous association studies of tramadol 
vs hypoglycemia and the lack of that association with oxycodone and codeine18,19. Additionally, we provided 
the evidence for no significant elevation of hypoglycemia ADRs in nine other opioids with the single significant 
exception of methadone. The hypothesis of SNRI or NMDAR relation to hypoglycemia led us to analyze the 
related drugs. To our surprise we found no evidence of significant elevation in hypoglycemia reports in the SNRI 
ADRs co-occurring with hypoglycemia %
Hypoglycemia 100.00
Hypotension 31.70
Respiratory failure 26.83
Miosis 21.95
Accidental overdose 14.63
QT prolongation 12.20
Depressed level of consciousness 12.20
Coma 12.20
Sinus tachycardia 9.76
Respiratory depression 9.76
Pneumonia 9.76
Involuntary muscle contractions 9.76
Hyperinsulinemic hypoglycemia 9.76
Cyanosis 9.76
Accidental exposure to product by child 9.76
Accidental exposure to product 9.76
Ventricular extrasystoles 7.32
Unresponsive to stimuli 7.32
Somnolence 7.32
Intentional overdose 7.32
Hypoventilation 7.32
Blood insulin increased 7.32
Abnormal respiration 4.88
Overdose 4.88
Muscle tightness 4.88
Mental disorder 4.88
Bradypnea 4.88
Blood glucose decreased 4.88
Adrenal insufficiency 4.88
Table 5. ADRs co-occurring with hypoglycemia in the methadone monotherapy cohort. Frequencies over 3% 
reported.
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and NMDAR antagonist cohorts. These findings imply that opioid receptor agonism, serotonin and norepineph-
rine reuptake, and N-methyl-D-aspartate receptor antagonism alone did not correlate with elevation in hypogly-
cemia reports suggesting a subtler mechanism specific to tramadol and methadone.
Methadone use was associated with hypoglycemia in a study using animal models, where methadone signifi-
cantly decreased blood glucose levels in a dose-dependent manner, while morphine, fentanyl, levorphanol, oxy-
codone or morphine-6β-glucuronide did not show significant change from baseline glucose levels37. Furthermore 
some case reports38,39, and retrospective studies40 also show evidence of hypoglycemia association with metha-
done use.
Most of the ADRs co-occurring with hypoglycemia reports in the tramadol and methadone cohorts, shown in 
Tables 3 and 5, were common to the opioid class (depressed level of consciousness, vomiting, malaise, dizziness, 
respiratory failure, miosis etc.) or hypoglycemia related (decreased blood glucose, hypoglycemic coma), except 
for side effects unique to tramadol (convulsions, seizure), or methadone (QT prolongation, sinus tachycardia). 
Furthermore, methadone co-occurring ADRs included ‘hyper-insulinemic hypoglycemia’ and ‘increased blood 
insulin’, which may indicate one of the mechanisms of the observed hypoglycemia ADR. The full etiology of hypo-
glycemia for both tramadol and methadone needs further studies.
conclusion
In our study we observed increased risk of hypoglycemia ADRs in FAERS reports of tramadol with respect to 
other opioid, SNRI, and NMDAR modulating drug reports in patients without concurrent medication use and 
comorbidities. We observed a similar association between methadone monotherapy and hypoglycemia. It may 
be beneficial to monitor glucose levels when initiating tramadol or methadone in both diabetic and non-diabetic 
patients. Alternative opioids or non-opioid pain medications may be safer to use with patients at risk of hypogly-
cemia or any complications associated with hypoglycemia.
Study limitations. FDA FAERS/AERS reporting is voluntary. The calculated frequencies do not represent 
actual population frequencies. A recent study found that FAERS/AERS reporting can be biased by legal or scien-
tific variables as well as newsworthiness41. Another study has shown that FAERS/AERS reporting can be signifi-
cantly underreported for some drugs42. Absence of comprehensive medical records and lab values further limits 
the scope of our analysis. Some concurrent medications and comorbidities may be missing from the records 
due to underreporting which may introduce uncertainties in ADR frequencies, and reporting odds ratios. We 
cannot derive the physiological mechanism of the adverse event from the FAERS/AERS records. The reporting 
odds ratios represent frequency ratios of reported adverse effects and are not based on population incidences. As 
with any association study, causality cannot be inferred from association. The reported cases were not clinically 
evaluated for causality by experts.
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